Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Seres Therapeutics (MCRB) Prices 10.5M Share Common Offering at $21.50/Sh
-
Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock
-
Seres Therapeutics (MCRB) to Offer 8M Common Shares
-
Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
-
Seres Therapeutics (MCRB) PT Raised to $38 at Canaccord Genuity, Following Drug Trial Results
-
Seres Therapeutics (MCRB) PT Lowered to $11 at Canaccord Genuity
-
Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
-
Seres Therapeutics (MCRB) PT Lowered to $15 at Canaccord Genuity; Maintains Buy
-
Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
-
Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
-
Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
-
Seres Therapeutics to Present at Canaccord Genuity 35th Annual Growth Conference
-
Canaccord Genuity Starts Seres Therapeutics (MCRB) at Buy
-
Seres Therapeutics Announces Closing of Initial Public Offering
-
Seres Therapeutics (MCRB) IPO Opens Up 58%
-
Seres Therapeutics (MCRB) IPO Prices at $18, Above Expected Range
-
Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering
-
Seres Therapeutics (MCRB) Sees IPO Price of $15 - $17/Share
-
Seres Therapeutics (MCRB) Files for $100M IPO
